GlassScriptPhysician profile
Francis Obeng
NPI 1902866601
$8,800.50
in general payments reported to CMS, 2019-2025
46 companies · $2,243 in 2025
The $2,243 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,084 · 2020: $811 · 2021: $147 · 2022: $544 · 2023: $1,299 · 2024: $1,674 · 2025: $2,243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,215.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,668.22 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,662.42 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $717.14 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $522.34 | 2019-2025 | |
| Lilly USA, LLC | $520.83 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $512.36 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $290.28 | 2019-2025 | Jardiance, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $236.93 | 2022-2025 | |
| Amgen INC. | $221.34 | 2019-2025 | Repatha, Otezla, Repatha |
| Kowa Pharmaceuticals America, INC. | $211.15 | 2019-2025 | Zoryve, Livalo |
| Abbott Laboratories | $207.66 | 2019-2025 | Freestyle Libre 3, Proclaim |
| Astellas Pharma US INC | $177.39 | 2019-2023 | Myrbetriq |
| Idorsia Pharmaceuticals US INC | $175.83 | 2022-2025 | Tryvio, Quviviq |
| Mannkind Corporation | $161.71 | 2022-2023 | Afrezza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $141.35 | 2019-2024 | Xifaxan, Trulance |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Francis Obeng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.